NEWS
Phase III trial initiation for Kinisoquin™ in cancer-associated thrombosis (CAT)
Phase III in Sickle Cell Disease (SCD)
Phase II trial with Administration for Strategic Preparedness and Response (ASPR)
Kinisoquin™ is an investigational therapy in Phase 3 clinical development. It has not been approved for use by any regulatory authority.
